human galc protein Search Results


recombinant human galc  (R&D Systems)
93
R&D Systems recombinant human galc
Proof-of-concept efficacy in neonatal Twitcher mice. (A) Survival curve of Twitcher mice injected intravenously on PND0 with 50 μL of PBS (vehicle, n = 8; median survival 40.5 days) or with 1 × 10 11 GC of AAVhu68.CB7.hGALCco.rBG diluted in 50 μL PBS ( n = 6; median survival 49 days). *** p < 0.001 Log-rank (Mantel-Cox) test. (B) Survival curve of Twitcher mice injected in the lateral cerebral ventricle (ICV) on PND0 with 2 μL of PBS (vehicle, n = 8; median survival 43 days), with 2 × 10 10 GC of AAVhu68.CB7.hGALCco.rBG in 2 μL PBS (low dose, n = 10; median survival 62 days), with 5 × 10 10 GC of AAVhu68.CB7.hGALCco.rBG in 2 μL PBS (mid dose, n = 12; median survival 99 days), or with 1 × 10 11 GC of AAVhu68.CB7.hGALCco.rBG in 2 × 2 μL PBS (bilateral ICV, high dose, n = 12; median survival 130 days). **** p < 0.0001 Log-rank (Mantel-Cox) test. (C) Neuromotor function assessed by the accelerated rotarod test on PND35 in mice treated via neonatal ICV administration [same animals as in (B) ]. ** p < 0.01, *** p < 0.001, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. (D) <t>GALC</t> enzyme activity in brain lysate from tissue obtained at humane endpoint in animals administered IV or ICV [same animals as in (A, B) ]. * p < 0.05, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. GALC, galactosylceramidase; GC, genome copies; ICV, intracerebroventricular; IV, intravenous; PBS, phosphate-buffered saline; PND, postnatal day.
Recombinant Human Galc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human galc/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant human galc - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Proof-of-concept efficacy in neonatal Twitcher mice. (A) Survival curve of Twitcher mice injected intravenously on PND0 with 50 μL of PBS (vehicle, n = 8; median survival 40.5 days) or with 1 × 10 11 GC of AAVhu68.CB7.hGALCco.rBG diluted in 50 μL PBS ( n = 6; median survival 49 days). *** p < 0.001 Log-rank (Mantel-Cox) test. (B) Survival curve of Twitcher mice injected in the lateral cerebral ventricle (ICV) on PND0 with 2 μL of PBS (vehicle, n = 8; median survival 43 days), with 2 × 10 10 GC of AAVhu68.CB7.hGALCco.rBG in 2 μL PBS (low dose, n = 10; median survival 62 days), with 5 × 10 10 GC of AAVhu68.CB7.hGALCco.rBG in 2 μL PBS (mid dose, n = 12; median survival 99 days), or with 1 × 10 11 GC of AAVhu68.CB7.hGALCco.rBG in 2 × 2 μL PBS (bilateral ICV, high dose, n = 12; median survival 130 days). **** p < 0.0001 Log-rank (Mantel-Cox) test. (C) Neuromotor function assessed by the accelerated rotarod test on PND35 in mice treated via neonatal ICV administration [same animals as in (B) ]. ** p < 0.01, *** p < 0.001, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. (D) GALC enzyme activity in brain lysate from tissue obtained at humane endpoint in animals administered IV or ICV [same animals as in (A, B) ]. * p < 0.05, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. GALC, galactosylceramidase; GC, genome copies; ICV, intracerebroventricular; IV, intravenous; PBS, phosphate-buffered saline; PND, postnatal day.

Journal: Human Gene Therapy

Article Title: Efficacy and Safety of a Krabbe Disease Gene Therapy

doi: 10.1089/hum.2021.245

Figure Lengend Snippet: Proof-of-concept efficacy in neonatal Twitcher mice. (A) Survival curve of Twitcher mice injected intravenously on PND0 with 50 μL of PBS (vehicle, n = 8; median survival 40.5 days) or with 1 × 10 11 GC of AAVhu68.CB7.hGALCco.rBG diluted in 50 μL PBS ( n = 6; median survival 49 days). *** p < 0.001 Log-rank (Mantel-Cox) test. (B) Survival curve of Twitcher mice injected in the lateral cerebral ventricle (ICV) on PND0 with 2 μL of PBS (vehicle, n = 8; median survival 43 days), with 2 × 10 10 GC of AAVhu68.CB7.hGALCco.rBG in 2 μL PBS (low dose, n = 10; median survival 62 days), with 5 × 10 10 GC of AAVhu68.CB7.hGALCco.rBG in 2 μL PBS (mid dose, n = 12; median survival 99 days), or with 1 × 10 11 GC of AAVhu68.CB7.hGALCco.rBG in 2 × 2 μL PBS (bilateral ICV, high dose, n = 12; median survival 130 days). **** p < 0.0001 Log-rank (Mantel-Cox) test. (C) Neuromotor function assessed by the accelerated rotarod test on PND35 in mice treated via neonatal ICV administration [same animals as in (B) ]. ** p < 0.01, *** p < 0.001, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. (D) GALC enzyme activity in brain lysate from tissue obtained at humane endpoint in animals administered IV or ICV [same animals as in (A, B) ]. * p < 0.05, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. GALC, galactosylceramidase; GC, genome copies; ICV, intracerebroventricular; IV, intravenous; PBS, phosphate-buffered saline; PND, postnatal day.

Article Snippet: We tested the sensitivity and specificity of the kit using recombinant human GALC (7310-GH; R&D Systems) and recombinant human beta-galactosidase (6464-GH; R&D Systems).

Techniques: Injection, Comparison, Activity Assay, Saline

MED study in juvenile postdisease onset Twitcher mice. (A) Compound clinical severity score in Twitcher mice treated on PND12–14 ICV with either 4 μL of artificial CSF (vehicle, n = 17), or 4 μL of AAVhu68.CB7.hGALCco.rBG at the following doses: 6.8 × 10 9 GC ( n = 16), 2 × 10 10 GC ( n = 17), 6.8 × 10 10 ( n = 17), or 2 × 10 11 GC ( n = 16). WT littermates were treated ICV with 4 μL of artificial CSF ( n = 17). The operator was blinded to the mice genotype and treatment. **** p < 0.0001 linear mixed-effect modeling comparing the clinical score change over time compared to the vehicle Twitcher group, alpha = 0.05. (B) Neuromotor function assessed by the accelerated rotarod test on PND35 in same mice as in (A) ** p < 0.01, *** p < 0.001, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. (C) GALC enzyme activity in brain (sagittal half), heart (sagittal half), and liver (half of the left lobe) lysate from tissue obtained either at scheduled necropsy (PND40, half of the animals) or humane endpoint (half of the animals) in the same animals as in (A) * p < 0.05, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. (D) Neuroinflammation quantification in the cerebral cortex, spinal cord, and sciatic nerve measured by mean object area of IBA1-positive cells stained by immunohistochemistry in tissues collected at the fixed necropsy time PND40. *** p < 0.001, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle-treated Twitcher mice. Representative images of IBA1 IHC from the vehicle groups (Twitcher and WT mice) and the HD group (2 × 10 11 GC, ICV PND12–14). CSF, cerebrospinal fluid; MED, minimum effective dose; WT, wild type.

Journal: Human Gene Therapy

Article Title: Efficacy and Safety of a Krabbe Disease Gene Therapy

doi: 10.1089/hum.2021.245

Figure Lengend Snippet: MED study in juvenile postdisease onset Twitcher mice. (A) Compound clinical severity score in Twitcher mice treated on PND12–14 ICV with either 4 μL of artificial CSF (vehicle, n = 17), or 4 μL of AAVhu68.CB7.hGALCco.rBG at the following doses: 6.8 × 10 9 GC ( n = 16), 2 × 10 10 GC ( n = 17), 6.8 × 10 10 ( n = 17), or 2 × 10 11 GC ( n = 16). WT littermates were treated ICV with 4 μL of artificial CSF ( n = 17). The operator was blinded to the mice genotype and treatment. **** p < 0.0001 linear mixed-effect modeling comparing the clinical score change over time compared to the vehicle Twitcher group, alpha = 0.05. (B) Neuromotor function assessed by the accelerated rotarod test on PND35 in same mice as in (A) ** p < 0.01, *** p < 0.001, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. (C) GALC enzyme activity in brain (sagittal half), heart (sagittal half), and liver (half of the left lobe) lysate from tissue obtained either at scheduled necropsy (PND40, half of the animals) or humane endpoint (half of the animals) in the same animals as in (A) * p < 0.05, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle Twitcher mice. (D) Neuroinflammation quantification in the cerebral cortex, spinal cord, and sciatic nerve measured by mean object area of IBA1-positive cells stained by immunohistochemistry in tissues collected at the fixed necropsy time PND40. *** p < 0.001, **** p < 0.0001, Kruskal-Wallis test followed by post hoc Dunn's multiple comparison test, alpha = 0.05, comparison to vehicle-treated Twitcher mice. Representative images of IBA1 IHC from the vehicle groups (Twitcher and WT mice) and the HD group (2 × 10 11 GC, ICV PND12–14). CSF, cerebrospinal fluid; MED, minimum effective dose; WT, wild type.

Article Snippet: We tested the sensitivity and specificity of the kit using recombinant human GALC (7310-GH; R&D Systems) and recombinant human beta-galactosidase (6464-GH; R&D Systems).

Techniques: Comparison, Activity Assay, Staining, Immunohistochemistry

ICM efficacy study in Krabbe dogs, nerve-conduction studies, CSF biomarkers, and MRI. (A) Nerve-conduction velocities in the radial (sensory), sciatic (motor), ulnar (motor), and tibial (motor) nerves in 2- to 3-week-old Krabbe dogs treated ICM with either (1) 1 mL of artificial CSF (vehicle, n = 2); or (2) 3 × 10 13 GC of AAVhu68.CB7.cGAMCco.rBG in 1 mL ( n = 4). A WT littermate that received 1 mL of artificial CSF ICM was used as a control. Two treated dogs were sacrificed at the scheduled timepoint of 6 months postinjection for tissue collection. Two treated dogs and the vehicle-treated Krabbe dogs were followed until humane endpoint. (B) Quantification of CSF psychosine and GalCer levels and CSF GALC enzyme activity. The dotted line represent the average GALC activity value from the serial CSF timepoints of the WT control (K928). (C) Brain MRI WM intensity semiquantitative scoring. (D) Brain MRI examples from one Krabbe vehicle dog (8 weeks), one Krabbe dog treated with AAV (10 weeks), and one WT control littermate (10 weeks). A dark hypointense WM represents normal myelination ( stars ); a grey isointense signal represents mild demyelination ( arrowhead ); a white hyperintense signal represents marked demyelination ( arrows ). AAV, adeno-associated virus; GalCer, galactosylceramide; ICM, intracisterna magna; MRI, magnetic resonance imaging; WM, white matter.

Journal: Human Gene Therapy

Article Title: Efficacy and Safety of a Krabbe Disease Gene Therapy

doi: 10.1089/hum.2021.245

Figure Lengend Snippet: ICM efficacy study in Krabbe dogs, nerve-conduction studies, CSF biomarkers, and MRI. (A) Nerve-conduction velocities in the radial (sensory), sciatic (motor), ulnar (motor), and tibial (motor) nerves in 2- to 3-week-old Krabbe dogs treated ICM with either (1) 1 mL of artificial CSF (vehicle, n = 2); or (2) 3 × 10 13 GC of AAVhu68.CB7.cGAMCco.rBG in 1 mL ( n = 4). A WT littermate that received 1 mL of artificial CSF ICM was used as a control. Two treated dogs were sacrificed at the scheduled timepoint of 6 months postinjection for tissue collection. Two treated dogs and the vehicle-treated Krabbe dogs were followed until humane endpoint. (B) Quantification of CSF psychosine and GalCer levels and CSF GALC enzyme activity. The dotted line represent the average GALC activity value from the serial CSF timepoints of the WT control (K928). (C) Brain MRI WM intensity semiquantitative scoring. (D) Brain MRI examples from one Krabbe vehicle dog (8 weeks), one Krabbe dog treated with AAV (10 weeks), and one WT control littermate (10 weeks). A dark hypointense WM represents normal myelination ( stars ); a grey isointense signal represents mild demyelination ( arrowhead ); a white hyperintense signal represents marked demyelination ( arrows ). AAV, adeno-associated virus; GalCer, galactosylceramide; ICM, intracisterna magna; MRI, magnetic resonance imaging; WM, white matter.

Article Snippet: We tested the sensitivity and specificity of the kit using recombinant human GALC (7310-GH; R&D Systems) and recombinant human beta-galactosidase (6464-GH; R&D Systems).

Techniques: Control, Activity Assay, Virus, Magnetic Resonance Imaging

ICM efficacy study in Krabbe dogs, neuroinflammation and GALC levels. (A) Representative pictures of IBA1 staining by IHC illustrating the macrophage/microglial neuroinflammation in Krabbe dogs treated with vehicle control or with AAV ICM. (B) Quantification of the mean area of the IBA1-positive signal in different neuroanatomical regions of the brain, spinal cord, and sciatic nerve of Krabbe dogs treated with AAV or vehicle. Each bar represents an animal. Error bars when present (cerebral cortical WM, corpus callosum, centrum semiovale, and internal capsule), represent the standard deviation from quantification of multiple slides when the neuroanatomical region was present on more than one brain section. (C) GALC activity in tissue lysate (50 μg protein per reaction, 2 h incubation) relative to the WT control ( dotted line ). Each bar represents one animal. WM, white matter.

Journal: Human Gene Therapy

Article Title: Efficacy and Safety of a Krabbe Disease Gene Therapy

doi: 10.1089/hum.2021.245

Figure Lengend Snippet: ICM efficacy study in Krabbe dogs, neuroinflammation and GALC levels. (A) Representative pictures of IBA1 staining by IHC illustrating the macrophage/microglial neuroinflammation in Krabbe dogs treated with vehicle control or with AAV ICM. (B) Quantification of the mean area of the IBA1-positive signal in different neuroanatomical regions of the brain, spinal cord, and sciatic nerve of Krabbe dogs treated with AAV or vehicle. Each bar represents an animal. Error bars when present (cerebral cortical WM, corpus callosum, centrum semiovale, and internal capsule), represent the standard deviation from quantification of multiple slides when the neuroanatomical region was present on more than one brain section. (C) GALC activity in tissue lysate (50 μg protein per reaction, 2 h incubation) relative to the WT control ( dotted line ). Each bar represents one animal. WM, white matter.

Article Snippet: We tested the sensitivity and specificity of the kit using recombinant human GALC (7310-GH; R&D Systems) and recombinant human beta-galactosidase (6464-GH; R&D Systems).

Techniques: Staining, Control, Standard Deviation, Activity Assay, Incubation